EVE Health Group (ASX:EVE) confirmed that all three resolutions put to shareholders at its Annual General Meeting held on 17 November 2026 were passed by way of poll, including the adoption of the Remuneration Report, the re-election of director Gregory Fry, and approval of an additional 10% placement capacity.
Key Points
- All three resolutions at the 17 November 2026 AGM were passed by poll.
- Resolution 1 — Adoption of Remuneration Report passed with 97.47% of votes in favour.
- Resolution 2 — Re-election of Director Gregory Fry passed with 98.90% of votes in favour.
- Resolution 3 — Approval of Additional 10% Capacity passed with 98.55% of votes in favour.
Remuneration Report and Director Re-election Results
At the AGM held on 17 November 2026, EVE Health Group's Resolution 1, the adoption of the Remuneration Report, was passed by poll with 29,267,209 votes in favour, representing 97.47% of votes cast, and 759,015 votes against, representing 2.53%. A total of 36,394,553 votes were recorded as abstentions. Resolution 2, covering the re-election of director Gregory Fry, was passed with 65,518,936 votes in favour, representing 98.90% of votes cast, and 730,577 votes against, representing 1.10%, with 171,264 abstentions recorded.
Additional 10% Placement Capacity Approved
Resolution 3, seeking approval of an additional 10% placement capacity, was passed by poll with 64,043,914 votes in favour, representing 98.55% of votes cast. A total of 945,352 votes were cast against the resolution, representing 1.45%, while 1,431,511 votes were recorded as abstentions. The proxy votes received for Resolution 3 included 64,038,334 directed in favour, 945,352 against, 1,431,511 abstentions, and 5,580 at the discretion of the proxy holder, according to the filing.
Voting Conduct and Disclosure Requirements
The company disclosed the results in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, which require the publication of proxy votes received and poll outcomes for each resolution considered at a general meeting. The filing was authorised for release by the Company Secretary. EVE Health Group describes itself as an Australian life sciences company focused on developing and commercialising pharmaceutical solutions, with lead assets including Dyspro®, targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction.



Please wait processing your request...